Response rates and key toxicities reported from pivotal BCMA-targeting trials and real-world data
| Generic name . | Commercial name . | ORR, % . | Median DOR . | CRS rates: Any grade (≥3), % . | Neuro toxicity rates: Any grade (≥3), % . | FDA approved . | Reference . |
|---|---|---|---|---|---|---|---|
| Idecabtagene vicleucel (ide-cel, also called bb2121) | Abecma | 73 | 10.7 mo | 84 (5) | 18 (3) | Yes | 58,61 |
| Real-World Consortium Data (ide-cel) | Abecma | 83 | NR | 82 (5) | 15 (5) | NA | 116 |
| Ciltacabtagene autoleucel (cilta-cel) | Carvikty | 97 | 21.8 mo | 95 (4) | 21 (9) | Yes | 60,62 |
| Meta-analysis BCMA-directed CAR-T including those in trial phase | NA | 78-85 | 14 mo* | NR (6.4-6.6) | NR (2.2-3.5) | NA | 117,118 |
| Teclistamab | Tecvayli | 63 | 18.4 mo | 72.1 (0.6) | 14.5 (0.6) | Pending decision at time of writing | 67 |
| DOR, duration of response; FDA, Food and Drug Administration; NA, not applicable. | |||||||
| Generic name . | Commercial name . | ORR, % . | Median DOR . | CRS rates: Any grade (≥3), % . | Neuro toxicity rates: Any grade (≥3), % . | FDA approved . | Reference . |
|---|---|---|---|---|---|---|---|
| Idecabtagene vicleucel (ide-cel, also called bb2121) | Abecma | 73 | 10.7 mo | 84 (5) | 18 (3) | Yes | 58,61 |
| Real-World Consortium Data (ide-cel) | Abecma | 83 | NR | 82 (5) | 15 (5) | NA | 116 |
| Ciltacabtagene autoleucel (cilta-cel) | Carvikty | 97 | 21.8 mo | 95 (4) | 21 (9) | Yes | 60,62 |
| Meta-analysis BCMA-directed CAR-T including those in trial phase | NA | 78-85 | 14 mo* | NR (6.4-6.6) | NR (2.2-3.5) | NA | 117,118 |
| Teclistamab | Tecvayli | 63 | 18.4 mo | 72.1 (0.6) | 14.5 (0.6) | Pending decision at time of writing | 67 |
| DOR, duration of response; FDA, Food and Drug Administration; NA, not applicable. | |||||||
Median PFS, not DOR reported.